- Home
- ARCT vs OMER Comparison
ARCT vs OMER Comparison
Compare ARCT & OMER Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARCT
- OMER
- Stock Information
- Founded
- ARCT 2013
- OMER 1994
- Country
- ARCT United States
- OMER United States
- Employees
- ARCT N/A
- OMER N/A
- Industry
- ARCT Biotechnology: Pharmaceutical Preparations
- OMER Biotechnology: Pharmaceutical Preparations
- Sector
- ARCT Health Care
- OMER Health Care
- Exchange
- ARCT Nasdaq
- OMER Nasdaq
- Market Cap
- ARCT 487.0M
- OMER 530.2M
- IPO Year
- ARCT N/A
- OMER 2009
- Fundamental
- Price
- ARCT $17.12
- OMER $8.37
- Analyst Decision
- ARCT Strong Buy
- OMER Buy
- Analyst Count
- ARCT 7
- OMER 4
- Target Price
- ARCT $65.00
- OMER $22.50
- AVG Volume (30 Days)
- ARCT 348.5K
- OMER 650.0K
- Earning Date
- ARCT 03-06-2025
- OMER 11-13-2024
- Dividend Yield
- ARCT N/A
- OMER N/A
- EPS Growth
- ARCT N/A
- OMER N/A
- EPS
- ARCT N/A
- OMER N/A
- Revenue
- ARCT $160,399,000.00
- OMER N/A
- Revenue This Year
- ARCT $7.33
- OMER N/A
- Revenue Next Year
- ARCT $4.71
- OMER N/A
- P/E Ratio
- ARCT N/A
- OMER N/A
- Revenue Growth
- ARCT N/A
- OMER N/A
- 52 Week Low
- ARCT $14.30
- OMER $2.61
- 52 Week High
- ARCT $45.00
- OMER $13.60
- Technical
- Relative Strength Index (RSI)
- ARCT 48.75
- OMER 42.71
- Support Level
- ARCT $15.82
- OMER $8.87
- Resistance Level
- ARCT $17.93
- OMER $9.50
- Average True Range (ATR)
- ARCT 1.51
- OMER 0.77
- MACD
- ARCT -0.04
- OMER -0.17
- Stochastic Oscillator
- ARCT 23.90
- OMER 5.25
About ARCT Arcturus Therapeutics Holdings Inc.
Arcturus Therapeutics Holdings Inc is an RNA medicines company focused on opportunities in rare diseases with a current focus on liver and respiratory diseases. It operates in the research and development segment of medical applications for nucleic acid-focused technology. The company's product pipeline includes LUNAR-OTC, LUNAR-CF, LUNAR-FLU and LUNAR-COV19.
About OMER Omeros Corporation
Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The lead drug candidate in the pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy.